Physicians' Academy for Cardiovascular Education

Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i

Meeting report with video, highlights and slides of a PACE-CME symposium held during virtual ERA-EDTA 2020 on the evolving role of SGLT2i in cardiovascular and kidney protection

Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

This e-learning course focusses on effects of SGLT2 inhibitors on outcomes in CKD patients and (potential) mechanisms of SGLT2 inhibitors. Member registration (free) is needed to enroll in this course.

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD
Prof. Wanner presents a case of a patient with CKD who develops diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.

Prof. Wanner presents a case of a CKD patient who has developed diabetes. He discusses what the optimal treatment strategy for such a patient is and how new treatments have resulted in a paradigm shift in nephrology.

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD
The mechanisms and beneficial cardiorenal effects of SGLT2 inhibitors in diabetic patients are dicussed in this video by Maria Rosa Costanzo, MD

Maria Rosa Constanzo explains the function of SGLT2 in the early proximal tubule of the kidney in detail and discusses how blockade of SGLT2 may result in beneficial effects.

Slides: Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

Slides (presentation) - June 10, 2020 - Christoph Wanner, MD – Würzburg, Germany - CME symposium held during ERA EDTA Virtual Congress 2020
This lecture by prof. Christoph Wanner was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: The cardiorenal connection & diabetes: Exploring opportunities for intervention

Slides (presentation) - June 10, 2020 - Maria Rosa Costanzo, MD – Naperville, IL, USA - CME symposium held during ERA EDTA Virtual Congress 2020
This lecture by prof. Maria Rosa Costanzo was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: Kidney protection and SGLT2i: What do we know?

Slides (presentation) - June 10, 2020 - Mark Cooper, MD – Melbourne, Australia - CME symposium held during ERA EDTA Virtual Congress 2020
This lecture by prof. Mark Cooper was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD
In this presention by prof. Mark Cooper, an overview is given of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2i, and their effect on kidney outcomes in CKD and DKD patients.

Prof. Mark Cooper gives an overview of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2 inhibitors, and their effect on kidney outcomes in CKD and DKD patients. With question

Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i